### Daunorubicin

**Section:** 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

<table>
<thead>
<tr>
<th><strong>Section</strong></th>
<th><strong>ATC codes:</strong> L01DB02</th>
<th><strong>Essential medicine status</strong></th>
<th><strong>ICD11 code:</strong> 2B30.0</th>
</tr>
</thead>
</table>

### Indication

Acute myeloid leukaemia with recurrent genetic abnormalities

### INN

Daunorubicin

### Medicine type

Chemical agent

### List type

Complementary (EML) (EMLc)

### Formulations

Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

### EML status history

First added in 1999 (TRS 895)
Changed in 2002 (TRS 914)
Changed in 2007 (TRS 950)
Changed in 2015 (TRS 994)
Changed in 2019 (TRS 1021)
Changed in 2023 (TRS 1049)

### Sex

All

### Age

Also recommended for children

### Therapeutic alternatives

The recommendation is for this specific medicine

### Patent information

Patents have expired in most jurisdictions
Read more about patents.

### Tags

Cancer

### Wikipedia

Daunorubicin

### DrugBank

Daunorubicin

---

**Summary of evidence and Expert Committee recommendations**

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of additional formulations of daunorubicin (injection 2 mg/mL and 5 mg/mL in vial and powder for injection 20 mg in vial) to the EML and EMLc.